Primary source Hovione: Hovione Completes €40 Million Expansion of Loures Tablet Manufacturing Center Adding Commercial-Scale Batch Tableting Capacity

Primary source Hovione: Hovione Opens New Facility at New Jersey Campus, Doubling U.S. Spray Drying Capacity
Scope note: this is small-molecule (chemical) pharmaceutical manufacturing (spray drying and tableting), not bioprocessing. We cover it in the Southern Europe Radar because Hovione's main global campus is in Loures, Portugal.
In two releases a month apart, the CDMO Hovione completed a tableting expansion at its main campus in Loures, Portugal (25 August 2026) and opened a new spray-drying building in East Windsor, New Jersey (16 September 2026). Both concern amorphous solid dispersions (ASDs) made by spray drying; in Loures, Hovione also compresses them into tablets at the same site.
Loures: a mirrored batch tableting line
- Investment: the expansion completes an investment cycle of more than EUR 40 million.
- Capacity: 25% more commercial-scale batch tableting capacity. The release also describes a 25% increase in the centre's manufacturing area.
- Design: a second line that mirrors the original across dispensing, blending, dry granulation, tableting and film coating, at the 300 to 400 kg batch scale, plus in-process control and staging areas.
- People: 50 new jobs at the Sete Casas facility, which employs about 1,250 people.
In 2022, Hovione invested in a continuous tablet manufacturing line at the same complex.
East Windsor: US spray-drying capacity doubled
The new 89 Twin Rivers building (31,000 sq ft, about 2,900 m2) adds two GMP-ready, commercial-scale PSD-3 spray dryers and, according to Hovione, doubles its US spray-drying capacity. It operates under the campus's existing FDA registration and completes a USD 100 million investment cycle in New Jersey. Hovione plans to develop about 15 acres of adjacent land into a 125,000 sq ft (about 11,600 m2) manufacturing facility over the next five to ten years, and offers customers the option to co-invest for priority access.


